TY - JOUR
T1 - Visual side effects associated with erectile dysfunction agents
AU - Fraunfelder, Frederick W.
N1 - Funding Information:
This study was supported in part by an unrestricted grant from Research to Prevent Blindness, New York, New York, and by the National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
PY - 2005/10
Y1 - 2005/10
N2 - PURPOSE: To describe the known ocular side effects of agents used to treat erectile dysfunction. DESIGN: Retrospective observational case series and literature review. METHODS: We reviewed 892 case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon), the Food and Drug Administration (FDA), and the World Health Organization (WHO) and conducted a comprehensive review of the literature. RESULTS: Ocular side effects of these drugs appear fully reversible and transitory. CONCLUSIONS: To date, evidence does not exist to discourage use of erectile dysfunction agents attributable to harmful ocular side effects. Ischemic optic neuropathy (ION) is "possible" by WHO classification, however, conclusive evidence linking ION to erectile dysfunction medications is still lacking.
AB - PURPOSE: To describe the known ocular side effects of agents used to treat erectile dysfunction. DESIGN: Retrospective observational case series and literature review. METHODS: We reviewed 892 case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute, Portland, Oregon), the Food and Drug Administration (FDA), and the World Health Organization (WHO) and conducted a comprehensive review of the literature. RESULTS: Ocular side effects of these drugs appear fully reversible and transitory. CONCLUSIONS: To date, evidence does not exist to discourage use of erectile dysfunction agents attributable to harmful ocular side effects. Ischemic optic neuropathy (ION) is "possible" by WHO classification, however, conclusive evidence linking ION to erectile dysfunction medications is still lacking.
UR - http://www.scopus.com/inward/record.url?scp=26844538190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26844538190&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2005.02.049
DO - 10.1016/j.ajo.2005.02.049
M3 - Article
C2 - 16226525
AN - SCOPUS:26844538190
SN - 0002-9394
VL - 140
SP - 723
EP - 724
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 4
ER -